GC Biopharma Plant Obtains WHO Pre-Qualification
South Korea facility expected to provide fill-finish capabilities.
The World Health Organization (WHO) has awarded prequalification to GC Biopharma, a biopharma company, for its fill-finish plant. Located in Ochang, South Korea, the complex is expected to produce drug products for vaccines (including sterile vials and pre-filled syringes), along with non-vaccine fill-finish and packaging. Established in 2019, the site is reportedly the largest fill-finish facility in the country.
According to the company, the new plant is equipped with an isolator facility and automation capabilities that power the entire process; it also employs a single-use system. GC Biopharma has supplied flu vaccines annually for the past three years through the Pan American Health Organization (PAHO) and the United Nations Children’s Fund (UNICEF).
“We hope [to] contribute to advancing global public health, based on our know-how and manufacturing capabilities that have produced and supplied vaccines for half a century," says EC Huh, PhD, president of GC Biopharma.
Newron, Myung In Pharm Form Partnership Centered Around Treating Schizophrenia in South Korea
January 14th 2025The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.
